Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA Using Oncomethylome Test in Drug Studies

NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today that it is collaborating with Merck KGaA to use its MGMT gene promoter methylation technology to select patients for trials for drugs to treat glioblastoma.

The Liege, Belgium-based company said it has begun testing for MGMT gene promoter methylation in a Phase II clinical trial for Merck KGaA's cilengitide and in a phase III clinical trial for newly diagnosed glioblastoma that has been ongoing since 2008, the company said.

The Phase III trial is attempting to demonstrate improvements in overall survival in patients with methylated MGMT gene promoter who are being treated with a combination therapy of cilengitide treatment along with temozolomide and radiation, which is the standard glioblastoma therapy.

In the Phase II trial, patients with unmethylated gene promoter are being enrolled and treated with an alternative cilengitide dosing schedule.

Under an earlier agreement, Merck KGaA acquired a non-exclusive, worldwide license to use the results of the MGMT methylation assay for glioblastoma treatment with cilengitide, for which the German company agreed to pay OncoMethylome fees for its testing services.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.